Chronos Archive seal
The Human Record

Evel Knievel

Case HR-RB001 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
October 17, 1938 – November 30, 2007
Synthetic DOB
1968-10-17
Index visit
2026-01-12 at age 57
Synthetic MRN
HR-RB001-SYN

Teaching objective: Find and treat chronic hepatitis C with cirrhosis in a 57-year-old former stunt performer who received many transfusions before 1992: raised transaminases and low platelets prompt hepatitis C antibody with reflex RNA; staging by FIB-4, elastography and ultrasound, with Child-Pugh and MELD-Na; the AASLD-IDSA simplified pathway for compensated cirrhosis with a pan-genotypic regimen (sofosbuvir-velpatasvir for 12 weeks), hepatitis B testing, a drug interaction check (proton pump inhibitor, statin) and hypoglycemia monitoring; cure confirmed by HCV RNA 12 or more weeks after treatment; Baveno VII use of liver stiffness and platelets to identify clinically significant portal hypertension and treat it with carvedilol instead of screening endoscopy; liver cancer surveillance by ultrasound with alpha-fetoprotein every six months that continues after cure; hepatitis A and B vaccination; transplant referral only if decompensation or a MELD-Na of 15 or more develops; pain care that is safe in cirrhosis (acetaminophen up to 2 g a day, no oral NSAIDs, no opioids, topical treatment, physical and aquatic therapy, sleep and coping skills); diabetes care adapted to cirrhosis, with continuous glucose monitoring because the A1c can read falsely low; alcohol counseling toward abstinence; and fall and fracture prevention, with bone density testing, vitamin D and an intravenous bisphosphonate, on the AASLD-IDSA HCV guidance, the AASLD 2023 HCC guidance, Baveno VII, the AASLD portal hypertension and ascites guidance, the ADA Standards of Care and the CMID diabetes and osteoporosis monographs.

Historical timeline

DateEventClaims
October 17, 1938Born Robert Craig Knievel in Butte, Montana; raised by his grandparents.CLM-0001
1965Begins his daredevil career with a touring motorcycle show.CLM-0002
1968Crashes after jumping the fountains at Caesars Palace, Las Vegas, and is hospitalized, by the obituaries' account in a coma for a month.CLM-0002
September 8, 1974Rocket-powered attempt to jump Idaho's Snake River Canyon fails.CLM-0003
1975Breaks his pelvis in the crash landing of a jump over 13 buses at Wembley Stadium; Guinness World Records later counts 433 fractures by the end of the year.CLM-0003, CLM-0004
1976Concussion and two broken arms in a jump attempt in Chicago; retires from major jumps.CLM-0003
1999Liver transplant after nearly dying of hepatitis C, likely acquired through a transfusion after a crash; reported to have stopped drinking at the time of the transplant.CLM-0005, CLM-0006
November 30, 2007Dies at 69 in Clearwater, Florida, of natural causes after years of diabetes, idiopathic pulmonary fibrosis, pain from his injuries and two strokes.CLM-0007, CLM-0008, CLM-0009

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Robert Craig Knievel was born on October 17, 1938, in the copper-mining town of Butte, Montana, and was raised by his grandparents. confirmed Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
HISTMED Master Roster v3 context
D He began his daredevil career in 1965 with a touring motorcycle show. His crash after jumping the fountains at Caesars Palace in Las Vegas, dated 1968 in the wire obituaries, put him in the hospital, by their account in a coma for a month.
One of the crashes behind the many fractures and the chronic pain in the modern episode. The length of the coma is disputed in later accounts.
probable Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
Evel Knievel dies at 69; had long been in failing health supports
Reuters. Daredevil Evel Knievel dies after long illness supports
D In 1974 his rocket-powered cycle failed in an attempt to jump Idaho's Snake River Canyon. In 1975 the crash landing of his jump over 13 buses at Wembley Stadium in London broke his pelvis. In the winter of 1976 an attempt to jump a tank of live sharks in Chicago left him with a concussion and two broken arms, after which he retired from major jumps.
More of the documented injuries behind the modern pain and fracture history.
confirmed Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
Evel Knievel dies at 69; had long been in failing health supports
Most broken bones in a lifetime supports
D Guinness World Records lists him as holding the record for the most broken bones in a lifetime, with 433 bone fractures by the end of 1975. His obituaries instead said he suffered nearly 40 broken bones before he retired in 1980.
The number of fractures is disputed; that he had very many fractures from crashes is not. The modern episode uses 'dozens of fractures' rather than either number.
disputed Most broken bones in a lifetime supports
Selbie J. Stunt legend Evel Knievel's unfortunate record after he broke his bones hundreds of times supports
Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes disputes
HISTMED Master Roster v3 context
D He had a liver transplant in 1999 after nearly dying of hepatitis C, which his obituaries said he likely contracted through a blood transfusion after one of his crashes.
The anchor for the modern episode: transfusion-acquired chronic hepatitis C with advanced liver disease, set three years before the transplant. The stage of his liver disease and any treatment before the transplant were not made public.
confirmed Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
Motorcycle daredevil Evel Knievel dies at 69 (The Associated Press) supports
Evel Knievel dies at 69; had long been in failing health supports
HISTMED Master Roster v3 context
D A news agency obituary reported that he did not quit drinking until his liver transplant in 1999.
Reported in an obituary; used in the modern episode only as a reason for alcohol counseling in liver disease, with no diagnosis of an alcohol use disorder.
probable Reuters. Daredevil Evel Knievel dies after long illness supports
HISTMED Master Roster v3 context
D In his last years he was in failing health with diabetes and idiopathic pulmonary fibrosis, an incurable scarring of the lungs, and had two strokes in the years before his death.
His diabetes is documented only in his last years; the modern episode places type 2 diabetes at the index age as a synthetic choice. The lung disease and strokes came after the index age and are not used in the modern episode.
confirmed Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
Motorcycle daredevil Evel Knievel dies at 69 (The Associated Press) supports
Evel Knievel dies at 69; had long been in failing health supports
D His final years were plagued by pain from his accidents. In a newspaper interview published early in 2007 he was described as frail and reliant on an oxygen tank and an implanted drug pump to relieve his pain.
Chronic pain from old injuries is documented; the modern episode places it at the index age and manages it without opioids.
confirmed Reuters. Daredevil Evel Knievel dies after long illness supports
D He died on November 30, 2007, at 69, at his condominium in Clearwater, Florida, after having trouble breathing; his death was reported as from natural causes.
History only, stated without detail. The roster's statement that pulmonary fibrosis caused his death is not stated by the obituaries fetched, which give natural causes after years of diabetes and pulmonary fibrosis.
confirmed Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes supports
Selbie J. Stunt legend Evel Knievel's unfortunate record after he broke his bones hundreds of times supports
Evel Knievel dies at 69; had long been in failing health supports
HISTMED Master Roster v3 context

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered resolved confirmed active
S Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C resolved confirmed both_with_link CLM-0005
S Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding active confirmed both_with_link CLM-0005
S Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) active confirmed active
S Type 2 diabetes on metformin, A1c 7.4% active confirmed active CLM-0007
S Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids active confirmed both_with_link CLM-0002, CLM-0003, CLM-0004, CLM-0008
S Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9 active confirmed active
S Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-01-12 Hemoglobin [Mass/volume] in Blood 13.9 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-01-12 Leukocytes [#/volume] in Blood by Automated count 4.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-01-12 Platelets [#/volume] in Blood by Automated count 118 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-01-12 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-01-12 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-01-12 Creatinine [Mass/volume] in Serum or Plasma 0.92 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-01-12 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 97 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-01-12 Glucose [Mass/volume] in Serum or Plasma 162 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-01-12 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 88 U/L (high)
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-01-12 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 96 U/L (high)
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-01-12 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 104 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-01-12 Bilirubin.total [Mass/volume] in Serum or Plasma 1.1 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-01-12 Albumin [Mass/volume] in Serum or Plasma 3.6 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-01-12 INR in Platelet poor plasma by Coagulation assay 1.1
Reference 0.9-1.1
http://loinc.org · 6301-6
S 2026-01-12 Hemoglobin A1c/Hemoglobin.total in Blood 7.4% (high)
Reference Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis
http://loinc.org · 4548-4
S 2026-01-12 Cholesterol [Mass/volume] in Serum or Plasma 186 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-01-12 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 mg/dL (high)
Reference Goal below 100 mg/dL in diabetes, below 70 if higher risk
http://loinc.org · 13457-7
S 2026-01-12 Cholesterol in HDL [Mass/volume] in Serum or Plasma 38 mg/dL (low)
Reference >=40 mg/dL
http://loinc.org · 2085-9
S 2026-01-12 Triglyceride [Mass/volume] in Serum or Plasma 178 mg/dL (high)
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-01-12 Albumin/Creatinine [Mass Ratio] in Urine 18 mg/g
Reference <=29 mg/g
http://loinc.org · 9318-7
S 2026-01-12 Total score [AUDIT-C] 7 http://loinc.org · 75626-2
S 2026-01-12 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-01-12 Pain severity - 0-10 verbal numeric rating [Score] - Reported 7 http://loinc.org · 72514-3
S 2026-01-26 Liver stiffness by US.transient elastography 26.8 kPa (high)
Reference Below 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertension
http://loinc.org · 77615-3
S 2026-01-26 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-01-26 Total score [AUDIT-C] 4 http://loinc.org · 75626-2
S 2026-01-26 Pain severity - 0-10 verbal numeric rating [Score] - Reported 6 http://loinc.org · 72514-3
S 2026-02-23 Hemoglobin [Mass/volume] in Blood 14 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-02-23 Leukocytes [#/volume] in Blood by Automated count 4.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-02-23 Platelets [#/volume] in Blood by Automated count 121 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-02-23 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-02-23 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 100 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-23 Glucose [Mass/volume] in Serum or Plasma 141 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-23 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 81 U/L (high)
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-02-23 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 90 U/L (high)
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-02-23 Bilirubin.total [Mass/volume] in Serum or Plasma 1 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-02-23 Albumin [Mass/volume] in Serum or Plasma 3.7 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-02-23 Calcium [Mass/volume] in Serum or Plasma 9.1 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-02-23 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 17 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-02-23 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 388 pg/mL
Reference 232-1245 pg/mL
http://loinc.org · 2132-9
S 2026-02-23 Thyrotropin [Units/volume] in Serum or Plasma 2.1 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-02-23 Total score [AUDIT-C] 1 http://loinc.org · 75626-2
S 2026-02-23 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-02-23 Pain severity - 0-10 verbal numeric rating [Score] - Reported 5 http://loinc.org · 72514-3
S 2026-05-18 Hemoglobin [Mass/volume] in Blood 14.2 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-05-18 Leukocytes [#/volume] in Blood by Automated count 5 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-05-18 Platelets [#/volume] in Blood by Automated count 129 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-05-18 Creatinine [Mass/volume] in Serum or Plasma 0.89 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-05-18 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 100 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-18 Glucose [Mass/volume] in Serum or Plasma 118 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-05-18 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-05-18 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-05-18 Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-05-18 Albumin [Mass/volume] in Serum or Plasma 3.9 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-05-18 Calcium [Mass/volume] in Serum or Plasma 9.3 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-05-18 Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 [IU]/mL
Reference Not detected is reported as 0; lower limit of quantification 15 IU/mL
http://loinc.org · 11011-4
S 2026-05-18 Hemoglobin A1c/Hemoglobin.total in Blood 6.4% (high)
Reference Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis
http://loinc.org · 4548-4
S 2026-05-18 Glucose management indicator 6.9%
Reference Individual goal below 7%
http://loinc.org · 97506-0
S 2026-05-18 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-05-18 Parathyrin.intact [Mass/volume] in Serum or Plasma 48 pg/mL
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 2026-05-18 Testosterone [Mass/volume] in Serum or Plasma 455 ng/dL
Reference 264-916 ng/dL
http://loinc.org · 2986-8
S 2026-05-18 Total score [AUDIT-C] 0 http://loinc.org · 75626-2
S 2026-05-18 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-05-18 Pain severity - 0-10 verbal numeric rating [Score] - Reported 4 http://loinc.org · 72514-3
S 2026-08-17 Hemoglobin [Mass/volume] in Blood 14.4 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-08-17 Leukocytes [#/volume] in Blood by Automated count 5.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-08-17 Platelets [#/volume] in Blood by Automated count 134 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-08-17 Creatinine [Mass/volume] in Serum or Plasma 0.88 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-08-17 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 100 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-08-17 Glucose [Mass/volume] in Serum or Plasma 112 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-08-17 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-08-17 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-08-17 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 92 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-08-17 Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-08-17 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-08-17 INR in Platelet poor plasma by Coagulation assay 1
Reference 0.9-1.1
http://loinc.org · 6301-6
S 2026-08-17 Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 [IU]/mL
Reference Not detected is reported as 0; lower limit of quantification 15 IU/mL
http://loinc.org · 11011-4
S 2026-08-17 Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.4 ng/mL
Reference <=8.3 ng/mL
http://loinc.org · 1834-1
S 2026-08-17 Hemoglobin A1c/Hemoglobin.total in Blood 6.3% (high)
Reference Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis
http://loinc.org · 4548-4
S 2026-08-17 Glucose management indicator 6.8%
Reference Individual goal below 7%
http://loinc.org · 97506-0
S 2026-08-17 Total score [AUDIT-C] 0 http://loinc.org · 75626-2
S 2026-08-17 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-08-17 Pain severity - 0-10 verbal numeric rating [Score] - Reported 4 http://loinc.org · 72514-3
S 2026-09-21 Cholesterol [Mass/volume] in Serum or Plasma 148 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-09-21 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 mg/dL
Reference Goal below 100 mg/dL in diabetes, below 70 if higher risk
http://loinc.org · 13457-7
S 2026-09-21 Cholesterol in HDL [Mass/volume] in Serum or Plasma 42 mg/dL
Reference >=40 mg/dL
http://loinc.org · 2085-9
S 2026-09-21 Triglyceride [Mass/volume] in Serum or Plasma 140 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-09-21 Prostate specific Ag [Mass/volume] in Serum or Plasma 1.3 ng/mL
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 2026-09-21 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-01-12Body height178 cm8302-2S
2026-01-12Body weight86 kg29463-7S
2026-01-12Body mass index (BMI) [Ratio]27.1 kg/m239156-5S
2026-01-12Systolic blood pressure138 mm[Hg]8480-6S
2026-01-12Diastolic blood pressure84 mm[Hg]8462-4S
2026-01-12Heart rate80 /min8867-4S
2026-01-12Respiratory rate14 /min9279-1S
2026-01-12Body temperature36.6 Cel8310-5S
2026-01-12Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-01-26Body height178 cm8302-2S
2026-01-26Body weight85.6 kg29463-7S
2026-01-26Body mass index (BMI) [Ratio]27 kg/m239156-5S
2026-01-26Systolic blood pressure136 mm[Hg]8480-6S
2026-01-26Diastolic blood pressure82 mm[Hg]8462-4S
2026-01-26Heart rate78 /min8867-4S
2026-01-26Respiratory rate14 /min9279-1S
2026-01-26Body temperature36.7 Cel8310-5S
2026-01-26Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-02-23Body height178 cm8302-2S
2026-02-23Body weight84.8 kg29463-7S
2026-02-23Body mass index (BMI) [Ratio]26.8 kg/m239156-5S
2026-02-23Systolic blood pressure128 mm[Hg]8480-6S
2026-02-23Diastolic blood pressure78 mm[Hg]8462-4S
2026-02-23Heart rate68 /min8867-4S
2026-02-23Respiratory rate14 /min9279-1S
2026-02-23Body temperature36.6 Cel8310-5S
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-05-18Body height178 cm8302-2S
2026-05-18Body weight83.2 kg29463-7S
2026-05-18Body mass index (BMI) [Ratio]26.3 kg/m239156-5S
2026-05-18Systolic blood pressure118 mm[Hg]8480-6S
2026-05-18Diastolic blood pressure72 mm[Hg]8462-4S
2026-05-18Heart rate62 /min8867-4S
2026-05-18Respiratory rate14 /min9279-1S
2026-05-18Body temperature36.5 Cel8310-5S
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-17Body height178 cm8302-2S
2026-08-17Body weight82.6 kg29463-7S
2026-08-17Body mass index (BMI) [Ratio]26.1 kg/m239156-5S
2026-08-17Systolic blood pressure120 mm[Hg]8480-6S
2026-08-17Diastolic blood pressure74 mm[Hg]8462-4S
2026-08-17Heart rate60 /min8867-4S
2026-08-17Respiratory rate14 /min9279-1S
2026-08-17Body temperature36.6 Cel8310-5S
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-09-21Body height178 cm8302-2S
2026-09-21Body weight82.4 kg29463-7S
2026-09-21Body mass index (BMI) [Ratio]26 kg/m239156-5S
2026-09-21Systolic blood pressure122 mm[Hg]8480-6S
2026-09-21Diastolic blood pressure74 mm[Hg]8462-4S
2026-09-21Heart rate62 /min8867-4S
2026-09-21Respiratory rate14 /min9279-1S
2026-09-21Body temperature36.6 Cel8310-5S
2026-09-21Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Hepatitis C confirmed or excluded and liver disease staged within three weeks2026-01-26completedChronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks
Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment2026-08-17completedHCV RNA not detected 13 weeks after a 12-week course
No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 152026-08-17completedNo decompensation; Child-Pugh A5; MELD-Na 6 after cure
No alcohol2026-08-17completedNo alcohol since the start of antiviral treatment; AUDIT-C 0
Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids2026-08-17completedPain 4 of 10; walking 30 minutes in the pool and on flat ground; no NSAIDs or opioids
Glucose management indicator below 7% without hypoglycemia2026-08-17completedGlucose management indicator 6.8%; no hypoglycemia
Vitamin D replete and osteoporosis treatment started; no falls with injury2026-08-17completedVitamin D 34 ng/mL; zoledronic acid given; no further falls

Interventions

InterventionStatusGuideline
Hepatology consultation within three weeks to confirm and stage chronic liver disease and plan antiviral treatment if hepatitis C is confirmedcompletedGL-AASLD-HCV-2026, GL-AASLD-HCC-2023
Liver work-up for raised transaminases and low platelets: hepatitis C antibody with reflex RNA, hepatitis B surface antigen, core antibody and surface antibody, hepatitis A IgG, HIV, INR, ultrasound of the abdomen, and FIB-4 from today's testscompletedGL-AASLD-HCV-2026, GL-USPSTF-HCV-2020
Pain care safe in liver disease: stop ibuprofen and omeprazole; acetaminophen up to 2 g a day; topical diclofenac for the knees; no opioids; physical and aquatic therapy; heat, pacing and sleep routines; pain coping skillscompletedGL-RAKOSKI-2018, GL-CDC-OPIOID-2022
Alcohol: brief counseling toward stopping completely, because alcohol speeds liver scarring; follow-up AUDIT-C at each visit; counseling or medicine for alcohol use offered if he cannot stopcompletedGL-USPSTF-ALC-2018, GL-AASLD-ALD-2019
Sofosbuvir-velpatasvir one tablet daily for 12 weeks under the AASLD-IDSA simplified pathway for compensated cirrhosis, after hepatitis B testing and a drug interaction check (no proton pump inhibitor; watch for muscle pain on atorvastatin); glucose monitoring for hypoglycemia; HCV RNA and liver tests 12 or more weeks after the last dosecompletedGL-AASLD-HCV-2026, GL-AASLD-HCV-MON, GL-EPCLUSA-LABEL
Carvedilol for clinically significant portal hypertension (liver stiffness 25 kPa or more), started at 6.25 mg and raised to 12.5 mg daily if blood pressure allows; no screening endoscopy while he takes it; liver stiffness and platelets rechecked a year after curecompletedGL-BAVENO-VII-2022, GL-AASLD-PH-2024
Liver cancer surveillance by ultrasound with alpha-fetoprotein every six months, continuing after cure because cirrhosis remainscompletedGL-AASLD-HCC-2023, GL-AASLD-HCV-2026
Vaccines for chronic liver disease: hepatitis A (two doses) and hepatitis B (two doses), then influenza, pneumococcal and zoster vaccines at the preventive visitcompletedGL-CDC-IMZ-2026, GL-AASLD-HCV-2026
Teaching on decompensation (swelling of the abdomen or legs, black stools or vomiting blood, confusion, yellow eyes) with same-day contact; transplant referral only if decompensation occurs or the MELD-Na reaches 15completedGL-AASLD-ASCITES-2021, GL-AASLD-PH-2024
Diabetes care adapted to cirrhosis: metformin continued while kidney function is normal and he does not drink; continuous glucose monitoring because the A1c can read falsely low; moderate-intensity statin; yearly eye and foot examinations and urine albumincompletedGL-ADA-4-2026, GL-ADA-6-2026, GL-CMID-2026
Falls and fractures: physical therapy and a home safety review; vitamin D; bone density scan, since cirrhosis, alcohol and many old fractures raise the risk of osteoporosiscompletedGL-ENDO-OSTEO-MEN-2012, GL-CMID-2026
Zoledronic acid 5 mg intravenously once a year, after vitamin D repletion and a normal calcium, rather than an oral bisphosphonate because of portal hypertension; dental review first; bone density again in two yearscompletedGL-ENDO-OSTEO-MEN-2012, GL-CMID-2026
Depression and distress screening at each visit, and plain explanations with written informationcompletedGL-USPSTF-DEP-2023, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Stacy M (Associated Press). Evel Knievel, iconic daredevil, dies at 69 of natural causes Lawrence Journal-World other
SRC-0002 Evel Knievel dies at 69; had long been in failing health ESPN.com news services other
SRC-0003 Reuters. Daredevil Evel Knievel dies after long illness Mail & Guardian other
SRC-0004 Most broken bones in a lifetime Guinness World Records other
SRC-0005 Selbie J. Stunt legend Evel Knievel's unfortunate record after he broke his bones hundreds of times Guinness World Records other
SRC-0006 Motorcycle daredevil Evel Knievel dies at 69 (The Associated Press) Deseret News other
SRC-0007 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the diagnostic pathway, the staging (FIB-4, elastography, Child-Pugh, MELD-Na), the choice of sofosbuvir-velpatasvir with the drug interaction check, carvedilol without screening endoscopy under Baveno VII, HCC surveillance after cure, the pain plan without NSAIDs or opioids, continuous glucose monitoring in cirrhosis, and zoledronic acid rather than an oral bisphosphonate.
provenance reviewnot_startedRecent-death rule: only what he made public, what was reported during his life, and obituaries and record-keeper accounts: the Associated Press, ESPN, Reuters, the Deseret News and Guinness World Records. The stage of his liver disease and any treatment before the 1999 transplant were not made public; everything clinical is synthetic.
safe messaging reviewnot_startedThe drinking reported in a Reuters obituary (CLM-0006) and the drug pump for pain in his last year (CLM-0008) are marked sensitive. No diagnosis of an alcohol or opioid use disorder is made; alcohol appears only as counseling and AUDIT-C scores, which are synthetic. Mood screens are synthetic and below the threshold for a safety assessment. His 1977 conviction is not medical and is left out. No relative is named or given a role.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.